Drug Patents Expiring in 2035
1. List of Absorica Ld drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750711 | SUN PHARM | Low dose oral pharmaceutical composition of isotretinoin |
May, 2035
(12 years from now) | |
| US9700535 | SUN PHARM | Oral pharmaceutical composition of isotretinoin |
Aug, 2035
(12 years from now) | |
Drugs and Companies using ISOTRETINOIN ingredient
Market Authorisation Date: 05 November, 2019
Treatment: NA
Dosage: CAPSULE;ORAL
ABSORICA LD family patents
5
United States
3
Mexico
2
Morocco
2
IB
2
Brazil
2
Australia
2
Canada
2
India
2
Russia
2
Japan
2
European Union
1
South Africa
2. List of Accrufer drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE;ORAL
ACCRUFER family patents
4
Japan
3
United Kingdom
3
China
3
European Union
2
Korea, Republic of
2
Australia
2
Spain
2
United States
2
Canada
1
Brazil
1
Chile
1
Poland
1
Saudi Arabia
1
Israel
1
Mexico
1
Slovenia
1
IB
1
South Africa
1
Singapore
1
EA
3. List of Adhansia Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 27, 2022 |
| M | Jun 28, 2024 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR family patents
14
United States
7
Canada
3
Australia
2
Chile
2
Singapore
2
Japan
1
Hong Kong
1
Korea, Republic of
1
Brazil
1
South Africa
1
Argentina
1
Israel
1
Taiwan, Province of China
1
Mexico
1
EA
1
China
1
European Union
4. List of Adrenalin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295657 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(12 years from now) | |
| US9119876 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(12 years from now) | |
| US10130592 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(12 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 December, 2012
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ADRENALIN family patents
10
United States
1
Korea, Republic of
1
Australia
1
Canada
1
China
1
Japan
1
European Union
5. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9415008
(Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(12 years from now) | |
|
US9066957
(Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(12 years from now) | |
| US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
10
United States
7
European Union
5
Israel
5
Japan
4
China
4
Australia
4
Spain
3
South Africa
2
Korea, Republic of
2
Brazil
2
Argentina
2
Canada
2
Taiwan, Province of China
2
EA
2
Mexico
1
Hong Kong
6. List of Akynzeo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 10 October, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
AKYNZEO family patents
6
United States
1
IB
1
Korea, Republic of
1
Australia
1
Canada
1
Taiwan, Province of China
1
China
1
Japan
1
European Union
7. List of Alecensa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433076 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(12 years from now) | |
| US10350214 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
ALECENSA family patents
4
United States
4
Japan
2
Korea, Republic of
2
Australia
2
Canada
2
Israel
2
Russia
2
Taiwan, Province of China
2
Singapore
2
China
1
Brazil
1
South Africa
1
Argentina
1
Malaysia
1
Mexico
1
European Union
8. List of Alunbrig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity (ODE) | May 22, 2027 |
| New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
ALUNBRIG family patents
6
United States
3
China
2
Korea, Republic of
2
Israel
2
Japan
2
European Union
1
RS
1
Australia
1
Chile
1
Lithuania
1
Ukraine
1
Dominican Republic
1
Spain
1
Mexico
1
Tunisia
1
Slovenia
1
Hungary
1
South Africa
1
Portugal
1
Colombia
1
Peru
1
Singapore
1
Croatia
1
EA
1
Philippines
1
Canada
1
New Zealand
1
Denmark
1
Costa Rica
1
Ecuador
9. List of Amvuttra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
AMVUTTRA family patents
12
United States
3
Singapore
3
Japan
3
European Union
2
Israel
2
China
1
Korea, Republic of
1
EA
1
Canada
1
Mexico
10. List of Aponvie drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 16 September, 2022
Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting
Dosage: EMULSION;INTRAVENOUS
APONVIE family patents
14
United States
3
Japan
1
Korea, Republic of
1
China
1
European Union
11. List of Arakoda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888558 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(12 years from now) | |
| US10342791 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
Drugs and Companies using TAFENOQUINE SUCCINATE ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 08 August, 2018
Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose
Dosage: TABLET;ORAL
ARAKODA family patents
6
United States
2
Australia
1
Hong Kong
1
Canada
1
Singapore
1
China
1
European Union
12. List of Arikayce Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446318 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(12 years from now) | |
| US10751355 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(12 years from now) | |
| US9895385 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(12 years from now) | |
| US10251900 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
17
United States
3
Spain
3
Japan
3
European Union
2
Korea, Republic of
2
Australia
2
Poland
2
Lithuania
2
Slovenia
2
Portugal
2
Croatia
2
Denmark
1
RS
1
Brazil
1
Mexico
1
Hungary
1
China
1
ME
1
Canada
1
New Zealand
13. List of Aristada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US11406632 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
8
United States
2
Australia
2
Israel
2
Russia
2
China
2
Japan
1
Morocco
1
Brazil
1
Canada
1
New Zealand
1
Mexico
1
European Union
14. List of Aristada Initio Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154552 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(12 years from now) | |
| US10849894 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(12 years from now) | |
| US10688091 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(12 years from now) | |
| US10016415 | ALKERMES INC | Aripiprazole prodrug compositions |
Sep, 2035
(12 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
6
United States
4
European Union
3
Japan
3
China
2
RS
2
Poland
2
Lithuania
2
Spain
2
Israel
2
Slovenia
2
Hungary
2
Portugal
2
Russia
2
Croatia
2
Denmark
1
Brazil
1
Australia
1
Cyprus
1
Mexico
1
Turkey
1
Canada
15. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
10
United States
7
European Union
5
Israel
5
Japan
4
China
4
Australia
4
Spain
3
South Africa
2
Korea, Republic of
2
Brazil
2
Argentina
2
Canada
2
Taiwan, Province of China
2
EA
2
Mexico
1
Hong Kong
16. List of Axumin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(12 years from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(12 years from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(12 years from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(12 years from now) | |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment
Dosage: SOLUTION;INTRAVENOUS
17. List of Bafiertam drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814692 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9636318 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9814691 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US10105336 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9820961 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US10098863 | BANNER LIFE SCIENCES | Fumarate esters |
Feb, 2035
(12 years from now) | |
| US9566259 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9636319 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US10105337 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9326947 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(12 years from now) | |
| US9820960 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9517209 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US10105335 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9511043 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9326965 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(12 years from now) | |
| US10918616 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Jun, 2035
(12 years from now) | |
| US10918617 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Aug, 2035
(12 years from now) | |
| US10918615 | BANNER LIFE SCIENCES | Fumarate esters |
Aug, 2035
(12 years from now) | |
| US10945985 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Aug, 2035
(12 years from now) | |
Drugs and Companies using MONOMETHYL FUMARATE ingredient
Market Authorisation Date: 28 April, 2020
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
BAFIERTAM family patents
34
United States
4
Australia
3
European Union
2
Spain
2
Canada
2
Israel
2
Denmark
18. List of Balversa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 12, 2024 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
BALVERSA family patents
3
United States
3
European Union
1
Morocco
1
RS
1
Korea, Republic of
1
Australia
1
Chile
1
Poland
1
Lithuania
1
Ukraine
1
Jordan
1
Spain
1
Israel
1
Cyprus
1
Mexico
1
Japan
1
Slovenia
1
Hungary
1
Argentina
1
South Africa
1
Portugal
1
Singapore
1
EA
1
China
1
Croatia
1
Turkey
1
Philippines
1
New Zealand
1
Canada
1
Taiwan, Province of China
1
Denmark
1
Costa Rica
1
Nicaragua
19. List of Biktarvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9708342 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10385067 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
| New Patient Population (NPP) | Jun 18, 2022 |
| M | Feb 24, 2024 |
NCE-1 date: February, 2022
Market Authorisation Date: 07 February, 2018
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
BIKTARVY family patents
5
United States
4
Japan
2
Morocco
2
Australia
2
Moldova, Republic of
2
Mexico
2
EA
2
China
2
Taiwan, Province of China
2
European Union
1
RS
1
Korea, Republic of
1
Brazil
1
Chile
1
Poland
1
Cuba
1
Malaysia
1
Lithuania
1
Ukraine
1
Dominican Republic
1
Uruguay
1
Spain
1
Israel
1
Cyprus
1
Slovenia
1
Hungary
1
Argentina
1
Portugal
1
El Salvador
1
Peru
1
Singapore
1
Croatia
1
Turkey
1
ME
1
Philippines
1
Norway
1
New Zealand
1
Canada
1
Denmark
1
Costa Rica
1
Ecuador
20. List of Brexafemme drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10174074 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| US10927142 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 1, 2026 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 1, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: June, 2030
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET;ORAL
BREXAFEMME family patents
5
United States
2
European Union
1
Slovenia
1
Hong Kong
1
RS
1
Hungary
1
EA
1
Spain
1
Portugal
1
Poland
1
Lithuania
1
Denmark
1
Croatia
1
China
21. List of Bunavail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(12 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
BUNAVAIL family patents
8
United States
1
Brazil
1
Australia
1
Canada
1
China
1
Japan
1
European Union
22. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
| New Indication (I) | Nov 21, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab
Dosage: CAPSULE;ORAL
CALQUENCE family patents
12
United States
3
IB
3
Taiwan, Province of China
2
Argentina
1
Korea, Republic of
1
Australia
1
Canada
1
EA
1
China
1
Japan
1
European Union
23. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily
Dosage: TABLET;ORAL
CALQUENCE family patents
12
United States
3
IB
3
Taiwan, Province of China
2
Argentina
1
Korea, Republic of
1
Australia
1
Canada
1
EA
1
China
1
Japan
1
European Union
24. List of Cinvanti drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 09 November, 2017
Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
CINVANTI family patents
14
United States
3
Japan
1
Korea, Republic of
1
China
1
European Union
25. List of Cyclophosphamide drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662342 | EUGIA PHARMA SPECLTS | Formulations of cyclophosphamide liquid concentrate |
Jun, 2035
(12 years from now) | |
Drugs and Companies using CYCLOPHOSPHAMIDE ingredient
Market Authorisation Date: 25 August, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE family patents
5
United States
1
Korea, Republic of
1
Brazil
1
Australia
1
Canada
1
Russia
1
China
1
Japan
1
European Union
26. List of Dayvigo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2025 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
5
United States
2
Singapore
2
Japan
1
China
1
Korea, Republic of
1
Brazil
1
Australia
1
Russia
1
Spain
1
Canada
1
Israel
1
Mexico
1
European Union
27. List of Definity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11395856 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
| US10022460 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(12 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
DEFINITY family patents
6
United States
2
Hong Kong
2
Australia
2
Israel
2
Taiwan, Province of China
2
Mexico
2
China
2
Japan
1
Korea, Republic of
1
Brazil
1
South Africa
1
Spain
1
Canada
1
EA
1
European Union
28. List of Epidiolex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11096905 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10709671 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11311498 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11357741 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11446258 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11154516 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9949937 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956186 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10092525 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956183 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10111840 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10137095 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10603288 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10709674 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956184 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956185 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10849860 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10966939 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10709673 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11065209 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US11400055 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US10918608 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
| New Patient Population (NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of focal seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with dravet syndrome; Use for the treatment of seizures in patients with tuberous sclerosis complex; Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with lennox-gastaut syndrome; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use for the treatment of atonic seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; Use for reducing seizure frequency in patients with tuberous sclerosis complex
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
33
United States
13
Japan
12
Australia
10
United Kingdom
9
Mexico
7
European Union
6
Canada
5
Israel
4
Brazil
4
Spain
3
Poland
2
RS
2
Lithuania
2
Slovenia
2
Hungary
2
Portugal
2
Croatia
2
Denmark
1
Hong Kong
29. List of Ermeza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345772 | MYLAN | Liquid levothyroxine formulations |
Feb, 2035
(12 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 29 April, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
30. List of Eskata drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
| US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
| US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
| US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
| US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(12 years from now) | |
Drugs and Companies using HYDROGEN PEROXIDE ingredient
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
ESKATA family patents
10
United States
1
Korea, Republic of
1
Denmark
1
Brazil
1
Australia
1
Spain
1
Portugal
1
Canada
1
Israel
1
Russia
1
Singapore
1
Mexico
1
China
1
Japan
1
European Union
31. List of Evrysdi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 7, 2027 |
| New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
| New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
EVRYSDI family patents
4
United States
3
European Union
2
Morocco
2
Korea, Republic of
2
Israel
2
Hungary
2
EA
1
RS
1
Brazil
1
Australia
1
Chile
1
Poland
1
Lithuania
1
Ukraine
1
Netherlands
1
Spain
1
Mexico
1
Japan
1
Slovenia
1
South Africa
1
Argentina
1
Portugal
1
Peru
1
Singapore
1
Croatia
1
China
1
Philippines
1
Norway
1
Canada
1
New Zealand
1
Taiwan, Province of China
1
Denmark
1
Costa Rica
32. List of Evzio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(12 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
33. List of Evzio (autoinjector) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(12 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
34. List of Exem Foam Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 7, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM;INTRAUTERINE
EXEM FOAM KIT family patents
4
United States
2
Netherlands
1
Denmark
1
Spain
1
Poland
1
European Union
35. List of Exkivity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(12 years from now) | |
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity (ODE) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chemotherapy
Dosage: CAPSULE;ORAL
EXKIVITY family patents
6
United States
4
Japan
3
European Union
2
Morocco
2
Korea, Republic of
2
Australia
2
Chile
2
Israel
2
Georgia
2
Singapore
2
China
2
New Zealand
1
RS
1
Brazil
1
Poland
1
Cuba
1
Lithuania
1
Saudi Arabia
1
Ukraine
1
Spain
1
Cyprus
1
Mexico
1
Tunisia
1
Slovenia
1
Hungary
1
South Africa
1
Portugal
1
Colombia
1
Peru
1
EA
1
ME
1
Croatia
1
Turkey
1
Philippines
1
Canada
1
Denmark
1
Costa Rica
1
Ecuador
36. List of Fetroja drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| New Indication (I) | Sep 25, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: NA
Dosage: POWDER;INTRAVENOUS
FETROJA family patents
6
Japan
3
Korea, Republic of
2
United States
2
China
2
European Union
1
Morocco
1
RS
1
Brazil
1
Australia
1
Poland
1
Lithuania
1
Malaysia
1
Spain
1
Mexico
1
Slovenia
1
Hungary
1
Portugal
1
Croatia
1
EA
1
Philippines
1
Canada
1
Taiwan, Province of China
1
Denmark
37. List of Fintepla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10950331 | ZOGENIX INC | Control system for control of distribution of medication |
Sep, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 25, 2027 |
| New Product (NP) | Jun 25, 2023 |
| New Indication (I) | Mar 25, 2025 |
| Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution
Dosage: SOLUTION;ORAL
FINTEPLA family patents
4
United States
2
Australia
2
New Zealand
2
Israel
2
Japan
2
European Union
1
China
1
IB
1
Korea, Republic of
1
Brazil
1
South Africa
1
Russia
1
Canada
1
Saudi Arabia
1
Singapore
1
Mexico
38. List of Firvanq Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959947 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
| US10959948 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
| US10959949 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
| US10959946 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
| US10688046 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
| US10493028 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(12 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea
Dosage: FOR SOLUTION;ORAL
FIRVANQ KIT family patents
13
United States
2
European Union
1
Australia
1
Spain
1
Canada
1
China
1
Japan
39. List of Genosyl drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10737051 | VERO BIOTECH | Nitrogen dioxide storage device |
Oct, 2035
(12 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
GENOSYL family patents
5
United States
3
Australia
3
Japan
1
Canada
1
European Union
40. List of Hetlioz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(12 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: CAPSULE;ORAL
HETLIOZ family patents
59
United States
22
Japan
19
Australia
18
Korea, Republic of
10
Canada
10
European Union
8
Mexico
8
China
5
Israel
4
Chile
4
Spain
4
Russia
4
New Zealand
2
Brazil
2
Slovenia
2
Hungary
2
Portugal
2
Colombia
2
Croatia
2
India
2
Denmark
1
Hong Kong
41. List of Hetlioz Lq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(12 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
59
United States
22
Japan
19
Australia
18
Korea, Republic of
10
Canada
10
European Union
8
Mexico
8
China
5
Israel
4
Chile
4
Spain
4
Russia
4
New Zealand
2
Brazil
2
Slovenia
2
Hungary
2
Portugal
2
Colombia
2
Croatia
2
India
2
Denmark
1
Hong Kong
42. List of Illuccix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027031 | TELIX | Kit for radiolabelling |
Jul, 2035
(12 years from now) | |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 17 December, 2021
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
ILLUCCIX family patents
10
United States
6
Australia
6
European Union
3
Canada
2
Brazil
2
Spain
2
Russia
2
New Zealand
2
Israel
2
Mexico
2
China
2
Japan
1
Hungary
1
South Africa
1
Belgium
1
Poland
1
Portugal
1
Denmark
43. List of Imbruvica drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9795604
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
|
US10463668
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
|
US10695350
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 25, 2022 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 2, 2024 |
| Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 13 November, 2013
Treatment: NA
Dosage: CAPSULE;ORAL
44. List of Impoyz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(12 years from now) | |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: NA
Dosage: CREAM;TOPICAL
IMPOYZ family patents
6
United States
2
Korea, Republic of
2
Japan
1
Brazil
1
Ukraine
1
Australia
1
Spain
1
Canada
1
New Zealand
1
Colombia
1
Mexico
1
Russia
1
EA
1
China
1
European Union
45. List of Inlyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(11 years from now) | |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
INLYTA family patents
6
United States
3
Japan
3
European Union
2
Poland
2
Spain
2
Slovenia
2
Hungary
2
Portugal
2
Singapore
1
Korea, Republic of
1
Brazil
1
Australia
1
Cyprus
1
Mexico
1
EA
1
China
1
Turkey
1
Canada
1
Taiwan, Province of China
1
Denmark
46. List of Isturisa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(12 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 6, 2025 |
| Orphan Drug Exclusivity (ODE) | Mar 6, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
ISTURISA family patents
4
United States
2
Japan
2
EA
2
European Union
1
Korea, Republic of
1
Australia
1
Chile
1
Poland
1
Lithuania
1
Spain
1
Israel
1
Cyprus
1
Mexico
1
Tunisia
1
Slovenia
1
IB
1
Hungary
1
Argentina
1
Portugal
1
Peru
1
Singapore
1
China
1
Croatia
1
Philippines
1
Canada
1
Taiwan, Province of China
1
Denmark
1
Ecuador
47. List of Jublia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient
Dosage: SOLUTION;TOPICAL
JUBLIA family patents
2
Japan
1
China
1
Korea, Republic of
1
Australia
1
Spain
1
Portugal
1
Canada
1
Poland
1
Russia
1
Taiwan, Province of China
1
Denmark
1
United States
1
Mexico
1
European Union
48. List of Kapspargo Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504655 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(12 years from now) | |
| US9700530 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(12 years from now) | |
Drugs and Companies using METOPROLOL SUCCINATE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
KAPSPARGO SPRINKLE family patents
5
United States
1
IB
1
Brazil
1
Australia
1
Canada
1
Mexico
1
Japan
1
European Union
49. List of Kengreal drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
Drugs and Companies using CANGRELOR ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
6
United States
2
Peru
1
Morocco
1
Korea, Republic of
1
Brazil
1
Chile
1
Canada
1
Colombia
1
Russia
1
Mexico
1
China
1
European Union
50. List of Kimyrsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 12, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: NA
Dosage: POWDER;INTRAVENOUS
KIMYRSA family patents
5
United States
1
Hong Kong
1
Brazil
1
Australia
1
New Zealand
1
Canada
1
Mexico
1
EA
1
China
1
Japan
1
European Union
51. List of Lenvima drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
| New Indication (I) | Aug 10, 2024 |
| M | Dec 19, 2024 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
Market Authorisation Date: 13 February, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
LENVIMA family patents
6
United States
4
Japan
4
European Union
2
Korea, Republic of
2
Jordan
2
Singapore
2
China
1
RS
1
Brazil
1
Australia
1
Poland
1
Lithuania
1
Spain
1
Mexico
1
Slovenia
1
Hungary
1
Argentina
1
Portugal
1
Russia
1
Croatia
1
Canada
1
Taiwan, Province of China
1
Denmark
52. List of Licart drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11344520 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(12 years from now) | |
| US11351133 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(12 years from now) | |
Drugs and Companies using DICLOFENAC EPOLAMINE ingredient
Market Authorisation Date: 19 December, 2018
Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released
Dosage: SYSTEM;TOPICAL
53. List of Lokelma drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(12 years from now) | |
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 18, 2023 |
| M | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
4
United States
2
EA
2
China
1
Hong Kong
1
Korea, Republic of
1
Brazil
1
Australia
1
Chile
1
Malaysia
1
Israel
1
Mexico
1
Japan
1
Argentina
1
South Africa
1
Philippines
1
Canada
1
Taiwan, Province of China
1
Costa Rica
1
European Union
54. List of Lonhala Magnair Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376661 | SUNOVION RESP | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(12 years from now) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
3
European Union
1
Spain
1
Canada
1
United States
1
China
55. List of Mavyret drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(12 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE48923
(Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(12 years from now) | |
|
US9321807
(Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
| New Patient Population (NPP) | Apr 30, 2022 |
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| New Dosing Schedule (D) | Sep 26, 2022 |
| M | Apr 10, 2023 |
| Pediatric Exclusivity (PED) | Feb 3, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: TABLET;ORAL
MAVYRET family patents
4
United States
2
Australia
2
Japan
1
Canada
1
Mexico
1
China
1
European Union
56. List of Narcan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9480644 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US10085937 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
| US9707226 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 November, 2015
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
NARCAN family patents
23
United States
3
Japan
3
European Union
2
Canada
2
Israel
2
Singapore
2
Russia
2
Mexico
2
China
1
Hong Kong
1
IB
1
United Kingdom
1
Australia
1
Spain
1
Germany
57. List of Nityr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10328029 | CYCLE PHARMS LTD | Pharmaceutical composition |
Jan, 2035
(11 years from now) | |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: TABLET;ORAL
NITYR family patents
2
United Kingdom
1
Slovenia
1
RS
1
Hungary
1
Spain
1
Portugal
1
Canada
1
Poland
1
Lithuania
1
Denmark
1
United States
1
Croatia
1
European Union
58. List of Obredon drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9549907 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(12 years from now) | |
| US10105324 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(12 years from now) | |
| US9808431 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(12 years from now) | |
Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 14 November, 2014
Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or increases the auc (0-inf) by at least 1.4
Dosage: SOLUTION;ORAL
59. List of Omlonti drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
OMLONTI family patents
15
United States
12
Japan
5
European Union
4
Spain
4
China
3
Korea, Republic of
3
Mexico
3
Canada
2
Hong Kong
2
Brazil
2
Australia
2